시장보고서

상품코드

1713230

세계의 의약품 시장 : 규모와 예측(2021-2031년), 지역 점유율, 동향, 성장 기회 - 분석 범위(분자유형별, 적응증별, 제품별, 유형별, 유통 채널별, 지역별)

Pharmaceuticals Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Molecule Type, Indication, Product, Type, Distribution Channel, and Geography

발행일: 2025년 04월 | 리서치사:

The Insight Partners | 페이지 정보: 영문 383 Pages | 배송안내 : 즉시배송

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 의약품 시장은 2024년 1조 7,577억 8,000만 달러에서 2031년에는 2조 8,403억 달러에 이를 것으로 예측되며, 2025년에서 2031년까지 CAGR 7.1%로 성장할 것으로 추정됩니다. 질병 부담 증가, 혁신적인 치료에 대한 수요 증가, 의약품에 대한 세계의 액세스 확대, 신흥 시장의 성장 등을 들 수 있어 예측 기간 중에 시장을 한층 더 밀어 올릴 가능성이 높습니다.

의약품 업계는 만성적이고 심각한 건강상태로 고통받는 사람들 증가를 주요 요인으로 매년 6%씩 정기적으로 성장하고 있습니다. 당뇨병 환자가 있으며 이 수치는 2030년까지 두배로 될 것으로 예상되고 있습니다.

이러한 병 증가에 대처하기 위해, 제약회사는 혁신적인 치료법을 낳는 연구개발에 다액의 투자를 실시했습니다. 또한 이탈리아만으로도 제약회사에 의해 연간 7억 유로가 임상시험에 투자되고 있어 의료기기회사를 포함하면 10억 유로에 달합니다. 미국 국립위생연구소, 미국 FDA, 제약회사 10개사, 비영리단체 5개 단체가 협력하여 희소질환으로 고통받는 3,000만명의 미국인을 위해 유전자 치료 개발을 가속시키는 등 관민 파트너십(PPP)의 역할이 높아지고 있는 것도 이를 뒷받침하고 있습니다.

COVID-19의 영향은 의약품 시장의 확대에도 크게 영향을 미치며, 2020년부터 2027년까지의 누적 시장 성장률은 순액으로 5,000억 달러에 이를 것으로 추정됩니다. 혁신적 의약품에 대한 수요는 계속 급증해, 특히 암 영역에서는 2027년까지 현재의 거의 2배가 되는 3,700억 달러에 달할 것으로 예측됩니다. 획기적인 세포 치료와 유전자 치료를 포함한 바이오 의약품은 2027년까지 세계 지출의 35%를 차지하게 되어 첨단 바이오 치료제로의 시프트를 나타냅니다.

경쟁기업별 분석은 제품 포트폴리오(제품 만족도, 제품의 특징, 이용가능성), 최근 시장 동향(합병인수, 신제품의 출시 및 강화, 투자 및 자금 조달, 수상, 합의, 제휴, 파트너십, 인지도, 사업 확대), 지역적 프레즌스에 기초하여 의약품 시장을 평가 및 분류해, 보다 좋은 의사결정을 지원합니다. 이 보고서는 세계 의약품 시장에서 주요 벤더의 최근 중요한 동향과 혁신에 대해 심층적으로 조사했습니다. 시장 주요 기업에는 Johnson & Johnson, Pfizer Inc, Merck & Co Inc, Eli Lilly and Co, Bristol-Myers Squibb Co, ESTEVE, UCB SA, Teva Pharmaceutical Industries Ltd, Hikma Pharmaceuticals Plc, Viatris Inc, AstraZeneca Plc, Sanofi SA, GSK PIc, F. Hoffmann-La Roche Ltd, Novartis AG, AbbVie Inc. 등이 있습니다.

의약품 시장은 분자 유형에 근거하여 저분자 제품, 생물학적 제제, 바이오시밀러 제품으로 구분됩니다. 제품별로 의약품 시장은 브랜드 의약품, 제네릭 의약품으로 구분됩니다.

의약품 시장에서 사업을 전개하는 기업은 다양한 유기적 및 무기적 전략을 채용하고 있습니다. 유기적 전략에는 주로, 제품 발매나 제품 승인이 포함됩니다. 비즈니스를 확대하고 지리적 존재를 높이고 시장 전체의 성장에 기여할 수 있습니다.

2025년 3월 Johnson & Johnson 산하의 Janssen-Cilag International NV는 유럽 의약품청의 인간용 의약품 위원회(CHMP)가 DARZALEX(일반명: 다라툼맙) 피하주(SC) 제제의 적응확대 승인을 권고했다고 발표했습니다.

의약품 시장 : 주요 시장 역학
시장 성장 촉진요인
- 세계의 질병 부담의 증대와 혁신적 치료에 대한 수요 증가
- 세계 의약품 접근 확대와 신흥 시장 성장
시장 성장 억제요인
- 규제에 의한 압력과 시장의 변화
시장 기회
- 혁신, AI, 시장 확대의 활용
향후의 동향
- 역내의 파워 시프트, 공급 체인의 다양화, 규제의 진화
성장 촉진요인과 억제요인의 영향

제6장 의약품 시장 : 세계 시장 분석

의약품 시장의 수익(2021-2031년)
의약품 시장 예측 및 분석

제7장 의약품 시장 분석 : 분자 유형별

저분자 제품
생물학적 제제 및 바이오시밀러 제제

제8장 의약품 시장 분석 : 적응증별

대사성 질환
암
면역학
호흡기 질환
심혈관 질환
신경질환
희귀질환
기타

제9장 의약품 시장 분석 : 제품별

브랜드
제네릭 의약품

제10장 의약품 시장 분석 : 유형별

처방약
시판약(OTC)

제11장 의약품 시장 분석 : 유통 채널별

병원 약국
소매 약국
온라인 약국

제12장 의약품 시장 : 지역별 분석

북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 스위스
- 기타 유럽
아시아태평양
- 중국
- 일본
- 인도
- 호주
- 한국
- 기타 아시아태평양
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
중남미
- 브라질
- 아르헨티나
- 기타 중남미

제13장 경쟁 구도

기업 점유율 분석

제14장 업계 정세

사업 확대
신제품 개발
기업 합병인수(M&A)
파트너십
기타 사업 전략

제15장 기업 프로파일

Johnson & Johnson
Pfizer Inc
Merck & Co Inc
Eli Lilly and Co
Bristol-Myers Squibb Co
ESTEVE
UCB SA
Teva Pharmaceutical Industries Ltd
Hikma Pharmaceuticals Plc
Viatris Inc
AstraZeneca Plc
Sanofi SA
GSK Plc
F. Hoffmann-La Roche Ltd
Novartis AG
AbbVie Inc

제16장 부록

JHS 25.05.07

The pharmaceuticals market is expected to reach US$ 2,840.30 billion by 2031 from US$ 1,757.78 billion in 2024; the market is estimated to grow at a CAGR of 7.1% during 2025-2031. Major factors driving the market growth include rising global disease burden and increasing demand for innovative treatments and expanding global access to medicines and growing emerging markets further are likely to boost the market during the forecast period. However, regulatory pressures and market shifts among the market deterrents.

The pharmaceutical industry regularly grows by 6% every year, primarily due to the increasing number of people suffering from chronic and severe health conditions. The global burden of diseases such as diabetes, obesity, cancer, and Alzheimer's continues to rise at an alarming rate, fueling the need for medical advancements. There are currently 171 million diabetics worldwide, and this figure is expected to double by 2030. Obesity affects 1.4 billion people, and projections estimate that this number will reach 3.3 billion by 2030. Furthermore, 18 million people suffer from Alzheimer's, and the number is likely to increase to 35 million by 2025.

To address these growing illnesses, pharmaceutical companies are investing heavily in research and development research and development to create innovative treatments. Additionally, € 700 million is invested annually in clinical trials by pharma companies in Italy alone, rising to € 1 billion if medical device companies are included. This is further supported by the increasing role of public-private partnerships (PPPs), such as the collaboration between the National Institutes of Health, the U.S. FDA, 10 pharmaceutical companies, and five non-profit organizations to accelerate gene therapy development for 30 million Americans suffering from rare diseases.

The impact of COVID-19 has also significantly shaped pharmaceutical market expansion, adding an estimated US$ 500 billion in net cumulative market growth from 2020 through 2027. While all regions have exceeded first-wave vaccination rates, booster utilization remains inconsistent, creating uncertainties about the future course of the pandemic. The demand for innovative drugs will continue to surge, particularly in oncology, where spending is projected to reach US$ 370 billion by 2027-almost double the current level. Moreover, specialty medicines will represent 43% of global spending by 2027 and 56% of total spending in developed markets. Biotech medicines, including breakthrough cell and gene therapies, will account for 35% of global spending by 2027, marking a shift toward advanced biotherapeutics.

The comparative company analysis evaluates and categorizes the pharmaceuticals market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global pharmaceuticals market. The key market players are Johnson & Johnson, Pfizer Inc, Merck & Co Inc, Eli Lilly and Co, Bristol-Myers Squibb Co, ESTEVE, UCB SA, Teva Pharmaceutical Industries Ltd, Hikma Pharmaceuticals Plc, Viatris Inc, AstraZeneca Plc, Sanofi SA, GSK PIc, F. Hoffmann-La Roche Ltd, Novartis AG, AbbVie Inc

Based on molecule type, the pharmaceuticals market is segmented into small molecule, biological and biosimilar products. In 2024, the small molecule, segment held the largest share of the market. Based on indication, the pharmaceuticals market is segmented into metabolic diseases, cancer, immunology, respiratory disorder, cardiovascular disorder, neurology disorder, rare disease, others. In 2024, the cancer segment held the largest share of the market. Based on product, the pharmaceuticals market is segmented into branded, generic. In 2024, the branded segment held the largest share of the market. Based on distribution channel, the pharmaceuticals market is segmented into hospital pharmacies, retail pharmacies, online pharmacies. In 2024, the hospital pharmacies segment held the largest share of the market.

Various organic and inorganic strategies are adopted by companies operating in the Pharmaceuticals Market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, along with contributing to the overall market growth. Furthermore, strategies such as acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the Pharmaceuticals Market are listed below.

In March 2025, Janssen-Cilag International NV, a Johnson & Johnson company, announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval for an expanded indication of DARZALEX (daratumumab) subcutaneous (SC) formulation. This recommendation is for its use in combination with bortezomib, lenalidomide, and dexamethasone (daratumumab-VRd) to treat adults with newly diagnosed multiple myeloma (NDMM).

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:

4. Pharmaceutical Market Landscape

4.1 Overview
4.2 PEST Analysis

5. Pharmaceutical Market - Key Market Dynamics

5.1 Pharmaceutical Market - Key Market Dynamics
5.2 Market Drivers
- 5.2.1 Rising Global Disease Burden and Increasing Demand for Innovative Treatments
- 5.2.2 Expanding Global Access to Medicines and Growing Emerging Markets
5.3 Market Restraints
- 5.3.1 Regulatory Pressures and Market Shifts
5.4 Market Opportunities
- 5.4.1 Harnessing Innovation, AI, and Market Expansion
5.5 Future Trends
- 5.5.1 Regional Power Shifts, Supply Chain Diversification, and Regulatory Evolution
5.6 Impact of Drivers and Restraints:

6. Pharmaceutical Market - Global Market Analysis

6.1 Pharmaceutical Market Revenue (US$ Billion), 2021-2031
6.2 Pharmaceutical Market Forecast Analysis

7. Pharmaceutical Market Analysis - by Molecule Type

7.1 Small Molecule
- 7.1.1 Overview
- 7.1.2 Small Molecule: Pharmaceutical Market - Revenue and Forecast to 2031 (US$ Billion)
7.2 Biological and Biosimilar Products
- 7.2.1 Overview
- 7.2.2 Biological and Biosimilar Products: Pharmaceutical Market - Revenue and Forecast to 2031 (US$ Billion)

8. Pharmaceutical Market Analysis - by Indication

8.1 Metabolic Diseases
- 8.1.1 Overview
- 8.1.2 Metabolic Diseases: Pharmaceutical Market - Revenue and Forecast to 2031 (US$ Billion)
8.2 Cancer
- 8.2.1 Overview
- 8.2.2 Cancer: Pharmaceutical Market - Revenue and Forecast to 2031 (US$ Billion)
8.3 Immunology
- 8.3.1 Overview
- 8.3.2 Immunology: Pharmaceutical Market - Revenue and Forecast to 2031 (US$ Billion)
8.4 Respiratory Disorder
- 8.4.1 Overview
- 8.4.2 Respiratory Disorder: Pharmaceutical Market - Revenue and Forecast to 2031 (US$ Billion)
8.5 Cardiovascular Disorder
- 8.5.1 Overview
- 8.5.2 Cardiovascular Disorder: Pharmaceutical Market - Revenue and Forecast to 2031 (US$ Billion)
8.6 Neurology Disorder
- 8.6.1 Overview
- 8.6.2 Neurology Disorder: Pharmaceutical Market - Revenue and Forecast to 2031 (US$ Billion)
8.7 Rare Disease
- 8.7.1 Overview
- 8.7.2 Rare Disease: Pharmaceutical Market - Revenue and Forecast to 2031 (US$ Billion)
8.8 Others
- 8.8.1 Overview
- 8.8.2 Others: Pharmaceutical Market - Revenue and Forecast to 2031 (US$ Billion)

9. Pharmaceutical Market Analysis - by Product

9.1 Branded
- 9.1.1 Overview
- 9.1.2 Branded: Pharmaceutical Market - Revenue and Forecast to 2031 (US$ Billion)
9.2 Generic
- 9.2.1 Overview
- 9.2.2 Generic: Pharmaceutical Market - Revenue and Forecast to 2031 (US$ Billion)

10. Pharmaceutical Market Analysis - by Type

10.1 Prescription
- 10.1.1 Overview
- 10.1.2 Prescription: Pharmaceutical Market - Revenue and Forecast to 2031 (US$ Billion)
10.2 OTC Drugs
- 10.2.1 Overview
- 10.2.2 OTC Drugs: Pharmaceutical Market - Revenue and Forecast to 2031 (US$ Billion)

11. Pharmaceutical Market Analysis - by Distribution Channel

11.1 Hospital Pharmacies
- 11.1.1 Overview
- 11.1.2 Hospital Pharmacies: Pharmaceutical Market - Revenue and Forecast to 2031 (US$ Billion)
11.2 Retail Pharmacies
- 11.2.1 Overview
- 11.2.2 Retail Pharmacies: Pharmaceutical Market - Revenue and Forecast to 2031 (US$ Billion)
11.3 Online Pharmacies
- 11.3.1 Overview
- 11.3.2 Online Pharmacies: Pharmaceutical Market - Revenue and Forecast to 2031 (US$ Billion)

12. Pharmaceutical Market - Geographical Analysis

12.1 Overview
12.2 North America
- 12.2.1 North America Pharmaceutical Market Overview
- 12.2.2 North America: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
- 12.2.3 North America: Pharmaceutical Market Breakdown, by Molecule Type
  - 12.2.3.1 North America: Pharmaceutical Market- Revenue and Forecast Analysis - by Molecule Type
- 12.2.4 North America: Pharmaceutical Market Breakdown, by Indication
  - 12.2.4.1 North America: Pharmaceutical Market- Revenue and Forecast Analysis - by Indication
- 12.2.5 North America: Pharmaceutical Market Breakdown, by Product
  - 12.2.5.1 North America: Pharmaceutical Market- Revenue and Forecast Analysis - by Product
- 12.2.6 North America: Pharmaceutical Market Breakdown, by Type
  - 12.2.6.1 North America: Pharmaceutical Market- Revenue and Forecast Analysis - by Type
- 12.2.7 North America: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.2.7.1 North America: Pharmaceutical Market- Revenue and Forecast Analysis - by Distribution Channel
- 12.2.8 North America: Pharmaceutical Market - Revenue and Forecast Analysis - by Country
  - 12.2.8.1 North America: Pharmaceutical Market - Revenue and Forecast Analysis - by Country
  - 12.2.8.2 United States: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.2.8.2.1 United States: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.2.8.2.2 United States: Pharmaceutical Market Breakdown, by Indication
    - 12.2.8.2.3 United States: Pharmaceutical Market Breakdown, by Product
    - 12.2.8.2.4 United States: Pharmaceutical Market Breakdown, by Type
    - 12.2.8.2.5 United States: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.2.8.3 Canada: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.2.8.3.1 Canada: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.2.8.3.2 Canada: Pharmaceutical Market Breakdown, by Indication
    - 12.2.8.3.3 Canada: Pharmaceutical Market Breakdown, by Product
    - 12.2.8.3.4 Canada: Pharmaceutical Market Breakdown, by Type
    - 12.2.8.3.5 Canada: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.2.8.4 Mexico: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.2.8.4.1 Mexico: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.2.8.4.2 Mexico: Pharmaceutical Market Breakdown, by Indication
    - 12.2.8.4.3 Mexico: Pharmaceutical Market Breakdown, by Product
    - 12.2.8.4.4 Mexico: Pharmaceutical Market Breakdown, by Type
    - 12.2.8.4.5 Mexico: Pharmaceutical Market Breakdown, by Distribution Channel
12.3 Europe
- 12.3.1 Europe Pharmaceutical Market Overview
- 12.3.2 Europe: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
- 12.3.3 Europe: Pharmaceutical Market Breakdown, by Molecule Type
  - 12.3.3.1 Europe: Pharmaceutical Market- Revenue and Forecast Analysis - by Molecule Type
- 12.3.4 Europe: Pharmaceutical Market Breakdown, by Indication
  - 12.3.4.1 Europe: Pharmaceutical Market- Revenue and Forecast Analysis - by Indication
- 12.3.5 Europe: Pharmaceutical Market Breakdown, by Product
  - 12.3.5.1 Europe: Pharmaceutical Market- Revenue and Forecast Analysis - by Product
- 12.3.6 Europe: Pharmaceutical Market Breakdown, by Type
  - 12.3.6.1 Europe: Pharmaceutical Market- Revenue and Forecast Analysis - by Type
- 12.3.7 Europe: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.3.7.1 Europe: Pharmaceutical Market- Revenue and Forecast Analysis - by Distribution Channel
- 12.3.8 Europe: Pharmaceutical Market - Revenue and Forecast Analysis - by Country
  - 12.3.8.1 Europe: Pharmaceutical Market - Revenue and Forecast Analysis - by Country
  - 12.3.8.2 United Kingdom: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.3.8.2.1 United Kingdom: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.3.8.2.2 United Kingdom: Pharmaceutical Market Breakdown, by Indication
    - 12.3.8.2.3 United Kingdom: Pharmaceutical Market Breakdown, by Product
    - 12.3.8.2.4 United Kingdom: Pharmaceutical Market Breakdown, by Type
    - 12.3.8.2.5 United Kingdom: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.3.8.3 Germany: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.3.8.3.1 Germany: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.3.8.3.2 Germany: Pharmaceutical Market Breakdown, by Indication
    - 12.3.8.3.3 Germany: Pharmaceutical Market Breakdown, by Product
    - 12.3.8.3.4 Germany: Pharmaceutical Market Breakdown, by Type
    - 12.3.8.3.5 Germany: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.3.8.4 France: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.3.8.4.1 France: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.3.8.4.2 France: Pharmaceutical Market Breakdown, by Indication
    - 12.3.8.4.3 France: Pharmaceutical Market Breakdown, by Product
    - 12.3.8.4.4 France: Pharmaceutical Market Breakdown, by Type
    - 12.3.8.4.5 France: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.3.8.5 Italy: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.3.8.5.1 Italy: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.3.8.5.2 Italy: Pharmaceutical Market Breakdown, by Indication
    - 12.3.8.5.3 Italy: Pharmaceutical Market Breakdown, by Product
    - 12.3.8.5.4 Italy: Pharmaceutical Market Breakdown, by Type
    - 12.3.8.5.5 Italy: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.3.8.6 Spain: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.3.8.6.1 Spain: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.3.8.6.2 Spain: Pharmaceutical Market Breakdown, by Indication
    - 12.3.8.6.3 Spain: Pharmaceutical Market Breakdown, by Product
    - 12.3.8.6.4 Spain: Pharmaceutical Market Breakdown, by Type
    - 12.3.8.6.5 Spain: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.3.8.7 Switzerland: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.3.8.7.1 Switzerland: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.3.8.7.2 Switzerland: Pharmaceutical Market Breakdown, by Indication
    - 12.3.8.7.3 Spain: Pharmaceutical Market Breakdown, by Product
    - 12.3.8.7.4 Spain: Pharmaceutical Market Breakdown, by Type
    - 12.3.8.7.5 Switzerland: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.3.8.8 Rest of Europe: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.3.8.8.1 Rest of Europe: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.3.8.8.2 Rest of Europe: Pharmaceutical Market Breakdown, by Indication
    - 12.3.8.8.3 Rest of Europe: Pharmaceutical Market Breakdown, by Product
    - 12.3.8.8.4 Rest of Europe: Pharmaceutical Market Breakdown, by Type
    - 12.3.8.8.5 Rest of Europe: Pharmaceutical Market Breakdown, by Distribution Channel
12.4 Asia Pacific
- 12.4.1 Asia Pacific Pharmaceutical Market Overview
- 12.4.2 Asia Pacific: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
- 12.4.3 Asia Pacific: Pharmaceutical Market Breakdown, by Molecule Type
  - 12.4.3.1 Asia Pacific: Pharmaceutical Market- Revenue and Forecast Analysis - by Molecule Type
- 12.4.4 Asia Pacific: Pharmaceutical Market Breakdown, by Indication
  - 12.4.4.1 Asia Pacific: Pharmaceutical Market- Revenue and Forecast Analysis - by Indication
- 12.4.5 Asia Pacific: Pharmaceutical Market Breakdown, by Product
  - 12.4.5.1 Asia Pacific: Pharmaceutical Market- Revenue and Forecast Analysis - by Product
- 12.4.6 Asia Pacific: Pharmaceutical Market Breakdown, by Type
  - 12.4.6.1 Asia Pacific: Pharmaceutical Market- Revenue and Forecast Analysis - by Type
- 12.4.7 Asia Pacific: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.4.7.1 Asia Pacific: Pharmaceutical Market- Revenue and Forecast Analysis - by Distribution Channel
- 12.4.8 Asia Pacific: Pharmaceutical Market - Revenue and Forecast Analysis - by Country
  - 12.4.8.1 Asia Pacific: Pharmaceutical Market - Revenue and Forecast Analysis - by Country
  - 12.4.8.2 China: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.4.8.2.1 China: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.4.8.2.2 China: Pharmaceutical Market Breakdown, by Indication
    - 12.4.8.2.3 China: Pharmaceutical Market Breakdown, by Product
    - 12.4.8.2.4 China: Pharmaceutical Market Breakdown, by Type
    - 12.4.8.2.5 China: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.4.8.3 Japan: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.4.8.3.1 Japan: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.4.8.3.2 Japan: Pharmaceutical Market Breakdown, by Indication
    - 12.4.8.3.3 Japan: Pharmaceutical Market Breakdown, by Product
    - 12.4.8.3.4 Japan: Pharmaceutical Market Breakdown, by Type
    - 12.4.8.3.5 Japan: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.4.8.4 India: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.4.8.4.1 India: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.4.8.4.2 India: Pharmaceutical Market Breakdown, by Indication
    - 12.4.8.4.3 India: Pharmaceutical Market Breakdown, by Product
    - 12.4.8.4.4 India: Pharmaceutical Market Breakdown, by Type
    - 12.4.8.4.5 India: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.4.8.5 Australia: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.4.8.5.1 Australia: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.4.8.5.2 Australia: Pharmaceutical Market Breakdown, by Indication
    - 12.4.8.5.3 Australia: Pharmaceutical Market Breakdown, by Product
    - 12.4.8.5.4 Australia: Pharmaceutical Market Breakdown, by Type
    - 12.4.8.5.5 Australia: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.4.8.6 South Korea: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.4.8.6.1 South Korea: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.4.8.6.2 South Korea: Pharmaceutical Market Breakdown, by Indication
    - 12.4.8.6.3 South Korea: Pharmaceutical Market Breakdown, by Product
    - 12.4.8.6.4 South Korea: Pharmaceutical Market Breakdown, by Type
    - 12.4.8.6.5 South Korea: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.4.8.7 Rest of APAC: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.4.8.7.1 Rest of APAC: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.4.8.7.2 Rest of APAC: Pharmaceutical Market Breakdown, by Indication
    - 12.4.8.7.3 Rest of APAC: Pharmaceutical Market Breakdown, by Product
    - 12.4.8.7.4 Rest of APAC: Pharmaceutical Market Breakdown, by Type
    - 12.4.8.7.5 Rest of APAC: Pharmaceutical Market Breakdown, by Distribution Channel
12.5 Middle East and Africa
- 12.5.1 Middle East and AfricaPharmaceutical Market Overview
- 12.5.2 Middle East and Africa: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
- 12.5.3 Middle East and Africa: Pharmaceutical Market Breakdown, by Molecule Type
  - 12.5.3.1 Middle East and Africa: Pharmaceutical Market- Revenue and Forecast Analysis - by Molecule Type
- 12.5.4 Middle East and Africa: Pharmaceutical Market Breakdown, by Indication
  - 12.5.4.1 Middle East and Africa: Pharmaceutical Market- Revenue and Forecast Analysis - by Indication
- 12.5.5 Middle East and Africa: Pharmaceutical Market Breakdown, by Product
  - 12.5.5.1 Middle East and Africa: Pharmaceutical Market- Revenue and Forecast Analysis - by Product
- 12.5.6 Middle East and Africa: Pharmaceutical Market Breakdown, by Type
  - 12.5.6.1 Middle East and Africa: Pharmaceutical Market- Revenue and Forecast Analysis - by Type
- 12.5.7 Middle East and Africa: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.5.7.1 Middle East and Africa: Pharmaceutical Market- Revenue and Forecast Analysis - by Distribution Channel
- 12.5.8 Middle East and Africa: Pharmaceutical Market - Revenue and Forecast Analysis - by Country
  - 12.5.8.1 Middle East and Africa: Pharmaceutical Market - Revenue and Forecast Analysis - by Country
  - 12.5.8.2 South Africa: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.5.8.2.1 South Africa: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.5.8.2.2 South Africa: Pharmaceutical Market Breakdown, by Indication
    - 12.5.8.2.3 South Africa: Pharmaceutical Market Breakdown, by Product
    - 12.5.8.2.4 South Africa: Pharmaceutical Market Breakdown, by Type
    - 12.5.8.2.5 South Africa: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.5.8.3 Saudi Arabia: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.5.8.3.1 Saudi Arabia: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.5.8.3.2 Saudi Arabia: Pharmaceutical Market Breakdown, by Indication
    - 12.5.8.3.3 Saudi Arabia: Pharmaceutical Market Breakdown, by Product
    - 12.5.8.3.4 Saudi Arabia: Pharmaceutical Market Breakdown, by Type
    - 12.5.8.3.5 Saudi Arabia: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.5.8.4 United Arab Emirates: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.5.8.4.1 United Arab Emirates: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.5.8.4.2 United Arab Emirates: Pharmaceutical Market Breakdown, by Indication
    - 12.5.8.4.3 United Arab Emirates: Pharmaceutical Market Breakdown, by Product
    - 12.5.8.4.4 United Arab Emirates: Pharmaceutical Market Breakdown, by Type
    - 12.5.8.4.5 United Arab Emirates: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.5.8.5 Rest of Middle East and Africa: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.5.8.5.1 Rest of Middle East and Africa: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.5.8.5.2 Rest of Middle East and Africa: Pharmaceutical Market Breakdown, by Indication
    - 12.5.8.5.3 Rest of Middle East and Africa: Pharmaceutical Market Breakdown, by Product
    - 12.5.8.5.4 Rest of Middle East and Africa: Pharmaceutical Market Breakdown, by Type
    - 12.5.8.5.5 Rest of Middle East and Africa: Pharmaceutical Market Breakdown, by Distribution Channel
12.6 South and Central America
- 12.6.1 South and Central AmericaPharmaceutical Market Overview
- 12.6.2 South and Central America: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
- 12.6.3 South and Central America: Pharmaceutical Market Breakdown, by Molecule Type
  - 12.6.3.1 South and Central America: Pharmaceutical Market- Revenue and Forecast Analysis - by Molecule Type
- 12.6.4 South and Central America: Pharmaceutical Market Breakdown, by Indication
  - 12.6.4.1 South and Central America: Pharmaceutical Market- Revenue and Forecast Analysis - by Indication
- 12.6.5 South and Central America: Pharmaceutical Market Breakdown, by Product
  - 12.6.5.1 South and Central America: Pharmaceutical Market- Revenue and Forecast Analysis - by Product
- 12.6.6 South and Central America: Pharmaceutical Market Breakdown, by Type
  - 12.6.6.1 South and Central America: Pharmaceutical Market- Revenue and Forecast Analysis - by Type
- 12.6.7 South and Central America: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.6.7.1 South and Central America: Pharmaceutical Market- Revenue and Forecast Analysis - by Distribution Channel
- 12.6.8 South and Central America: Pharmaceutical Market - Revenue and Forecast Analysis - by Country
  - 12.6.8.1 South and Central America: Pharmaceutical Market - Revenue and Forecast Analysis - by Country
  - 12.6.8.2 Brazil: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.6.8.2.1 Brazil: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.6.8.2.2 Brazil: Pharmaceutical Market Breakdown, by Indication
    - 12.6.8.2.3 Brazil: Pharmaceutical Market Breakdown, by Product
    - 12.6.8.2.4 Brazil: Pharmaceutical Market Breakdown, by Type
    - 12.6.8.2.5 Brazil: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.6.8.3 Argentina: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.6.8.3.1 Argentina: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.6.8.3.2 Argentina: Pharmaceutical Market Breakdown, by Indication
    - 12.6.8.3.3 Argentina: Pharmaceutical Market Breakdown, by Product
    - 12.6.8.3.4 Argentina: Pharmaceutical Market Breakdown, by Type
    - 12.6.8.3.5 Argentina: Pharmaceutical Market Breakdown, by Distribution Channel
  - 12.6.8.4 Rest of South and Central America: Pharmaceutical Market - Revenue, 2021 - 2031 (US$ Billion)
    - 12.6.8.4.1 Rest of South and Central America: Pharmaceutical Market Breakdown, by Molecule Type
    - 12.6.8.4.2 Rest of South and Central America: Pharmaceutical Market Breakdown, by Indication
    - 12.6.8.4.3 Rest of South and Central America: Pharmaceutical Market Breakdown, by Product
    - 12.6.8.4.4 Rest of South and Central America: Pharmaceutical Market Breakdown, by Type
    - 12.6.8.4.5 Rest of South and Central America: Pharmaceutical Market Breakdown, by Distribution Channel

13. Competitive Landscape

13.1 Company Market Share Analysis

14. Industry Landscape

14.1 Overview
14.2 Expansion
14.3 New Product Development
14.4 Merger and Acquisition
14.5 Partnerships
14.6 Other Business Strategies

15. Company Profiles

15.1 Johnson & Johnson
- 15.1.1 Key Facts
- 15.1.2 Business Description
- 15.1.3 Products and Services
- 15.1.4 Financial Overview
- 15.1.5 SWOT Analysis
- 15.1.6 Key Developments
15.2 Pfizer Inc
- 15.2.1 Key Facts
- 15.2.2 Business Description
- 15.2.3 Products and Services
- 15.2.4 Financial Overview
- 15.2.5 SWOT Analysis
- 15.2.6 Key Developments
15.3 Merck & Co Inc
- 15.3.1 Key Facts
- 15.3.2 Business Description
- 15.3.3 Products and Services
- 15.3.4 Financial Overview
- 15.3.5 SWOT Analysis
- 15.3.6 Key Developments
15.4 Eli Lilly and Co
- 15.4.1 Key Facts
- 15.4.2 Business Description
- 15.4.3 Financial Overview
- 15.4.4 SWOT Analysis
- 15.4.5 Key Developments
15.5 Bristol-Myers Squibb Co
- 15.5.1 Key Facts
- 15.5.2 Business Description
- 15.5.3 Products and Services
- 15.5.4 Financial Overview
- 15.5.5 SWOT Analysis
- 15.5.6 Key Developments
15.6 ESTEVE
- 15.6.1 Key Facts
- 15.6.2 Business Description
- 15.6.3 Products and Services
- 15.6.4 Financial Overview
- 15.6.5 SWOT Analysis
- 15.6.6 Key Developments
15.7 UCB SA
- 15.7.1 Key Facts
- 15.7.2 Business Description
- 15.7.3 Products and Services
- 15.7.4 Financial Overview
- 15.7.5 SWOT Analysis
- 15.7.6 Key Developments
15.8 Teva Pharmaceutical Industries Ltd
- 15.8.1 Key Facts
- 15.8.2 Business Description
- 15.8.3 Products and Services
- 15.8.4 Financial Overview
- 15.8.5 SWOT Analysis
- 15.8.6 Key Developments
15.9 Hikma Pharmaceuticals Plc
- 15.9.1 Key Facts
- 15.9.2 Business Description
- 15.9.3 Products and Services
- 15.9.4 Financial Overview
- 15.9.5 SWOT Analysis
- 15.9.6 Key Developments
15.10 Viatris Inc
- 15.10.1 Key Facts
- 15.10.2 Business Description
- 15.10.3 Products and Services
- 15.10.4 Financial Overview
- 15.10.5 SWOT Analysis
- 15.10.6 Key Developments
15.11 AstraZeneca Plc
- 15.11.1 1Key Facts
- 15.11.2 Business Description
- 15.11.3 Products and Services
- 15.11.4 Financial Overview
- 15.11.5 SWOT Analysis
- 15.11.6 Key Developments
15.12 Sanofi SA
- 15.12.1 Key Facts
- 15.12.2 Business Description
- 15.12.3 Products and Services
- 15.12.4 Financial Overview
- 15.12.5 SWOT Analysis
- 15.12.6 Key Developments
15.13 GSK Plc
- 15.13.1 Key Facts
- 15.13.2 Business Description
- 15.13.3 Products and Services
- 15.13.4 Financial Overview
- 15.13.5 SWOT Analysis
- 15.13.6 Key Developments
15.14 F. Hoffmann-La Roche Ltd
- 15.14.1 Key Facts
- 15.14.2 Business Description
- 15.14.3 Products and Services
- 15.14.4 Financial Overview
- 15.14.5 SWOT Analysis
- 15.14.6 Key Developments
15.15 Novartis AG
- 15.15.1 Key Facts
- 15.15.2 Business Description
- 15.15.3 Products and Services
- 15.15.4 Financial Overview
- 15.15.5 SWOT Analysis
- 15.15.6 Key Developments
15.16 AbbVie Inc
- 15.16.1 Key Facts
- 15.16.2 Business Description
- 15.16.3 Products and Services
- 15.16.4 Financial Overview
- 15.16.5 SWOT Analysis
- 15.16.6 Key Developments

16. Appendix

16.1 Glossary of Terms
16.2 About The Insight Partners